Armodafinil represents one of the most pharmacologically refined wakefulness-promoting agents developed in modern neuropharmacology, engineered specifically to manage debilitating sleep-wake dysregulations without the systemic sympathomimetic fallout typical of classical central nervous system stimulants. As the isolated enantiomeric refinement of racemic modafinil, the molecule embodies a sophisticated convergence between stereochemistry, neurobiology, and clinical therapeutics. By selectively amplifying alertness through targeted monoaminergic and peptidergic neuromodulation, armodafinil provides profound insights into the delicate neurochemical architecture orchestrating human vigilance, sustained attention, and circadian adaptation.
Armodafinil
1. Concise Definition
Armodafinil is an orally active, long-acting wakefulness-promoting agent (eugeroic) comprising exclusively the enantiopure (R)-enantiomer of the racemic parent compound modafinil. Pharmacologically classified as a selective, atypical dopamine reuptake inhibitor with secondary modulatory influences on hypothalamic wakefulness circuits, it is indicated primarily for the mitigation of excessive daytime sleepiness associated with narcolepsy, obstructive sleep apnea, and shift work sleep disorder.
In clinical neuropharmacology, armodafinil is distinguished by its pharmacokinetic superiority over racemic modafinil, characterized by prolonged systemic exposure and sustained therapeutic plasma concentrations throughout the active waking period. Unlike traditional psychostimulants such as amphetamines or methylphenidate, armodafinil facilitates robust cortical wakefulness with minimal peripheral cardiovascular excitation, low abuse liability, and a markedly reduced propensity for inducing stereotypic rebound hypersomnolence.
2. Etymology & Linguistic Origin
The International Nonproprietary Name (INN) armodafinil is derived through systematic chemical and pharmacological nomenclature. The prefix ar- is an alphabetic phonetic contraction denoting the (R)-enantiomer (from the Latin rectus, meaning “right” or “correct” in the Cahn-Ingold-Prelog stereochemical priority convention). This prefix is fused to the root generic name modafinil.
The base term modafinil itself was coined during the late 1970s and 1980s by the French pharmaceutical enterprise Laboratoire L. Lafon. The stem incorporates phonetic elements reflecting its chemical class—specifically, a benzhydryl sulfinyl acetamide derivative chemically designated as 2-[(R)-(diphenylmethyl)sulfinyl]acetamide. When Lafon and subsequently Cephalon isolated the single enantiomer to optimize half-life and bioavailability, the pharmaceutical modifier was appended to demarcate its optical purity and distinct pharmacokinetic profile from the racemic mixture.
3. Pronunciation & Grammatical Form
The standard phonetic transcription of armodafinil is /ˌɑːrmoʊˈdæfɪnɪl/ in General American English and /ˌɑːməʊˈdæfɪnɪl/ in Received Pronunciation. Grammatically, the term functions primarily as an uncountable proper noun designating a specific pharmacological entity, though it frequently appears as an attributive noun or noun adjunct in medical prose (e.g., “armodafinil administration,” “armodafinil therapy,” or “armodafinil pharmacokinetics”).
Accepted variants include its proprietary trade names, notably Nuvigil in the United States and various generic formulations worldwide. In formal biochemical literature, it may be referenced by its chemical identifier, (–)-2-[((R)-diphenylmethyl)sulfinyl]acetamide, or laboratory research code CEP-1538. It does not possess standard plural forms in clinical usage, though clinical researchers occasionally refer colloquially to comparative “armodafinil regimens.”
4. Detailed Conceptual Explanation
To fully conceptualize armodafinil, one must examine its place within the taxonomy of central nervous system therapeutics. Traditional psychostimulants act predominantly by inducing the vesicular release of catecholamines—namely dopamine and norepinephrine—or by competitively reversing monoamine transporters across widespread cerebral regions. This indiscriminate surge in neurochemistry precipitates widespread sympathomimetic stimulation, manifesting clinically as peripheral vasoconstriction, elevated mean arterial pressure, tachycardia, motor agitation, and heightened risk of psychological dependence. In sharp contrast, armodafinil occupies the specialized pharmacological category of eugeroics: agents that foster a state of natural, vigilant wakefulness without the peripheral excitation and euphoric reinforcement characteristic of amphetaminergic compounds.
At the molecular level, armodafinil exhibits stereoselective affinity for the cell-membrane dopamine active transporter (DAT). By binding to the DAT with a low-to-moderate affinity, it prevents the clearance of synaptic dopamine, thereby augmenting extracellular dopamine levels predominantly within the prefrontal cortex and nucleus accumbens. Crucially, the conformational engagement of armodafinil with the transporter diverges significantly from that of classic inhibitors like cocaine or methylphenidate. Its binding kinetics are characterized by slow association and dissociation constants, precluding the rapid neurochemical spikes that trigger intense reinforcing behaviors, drug craving, or behavioral sensitization.
Beyond isolated dopaminergic mechanisms, armodafinil exerts coordinated, downstream modulation across a network of hypothalamic sleep-wake centers. Electrophysiological and neuroimaging evidence illustrates that armodafinil activates the wake-active orexinergic (hypocretinergic) neurons situated within the perifornical and lateral hypothalamic areas. Concurrently, it stimulates tuberomammillary histaminergic transmission and enhances noradrenergic signaling arising from the locus coeruleus, while downregulating local gamma-aminobutyric acid (GABA) inhibitory tone within the anterior hypothalamic ventrolateral preoptic nucleus (VLPO). This targeted subcortical interplay stabilizes the flip-flop switch of sleep-wake regulation, preserving wakefulness by reinforcing physiological arousal circuitry while suppressing somnogenic drive.
The boundaries of armodafinil’s pharmacological scope are defined by its enantiomeric homogeneity. Racemic modafinil consists of an equimolar ratio of two optical isomers: the (S)-enantiomer and the (R)-enantiomer. The (S)-enantiomer exhibits rapid hepatic metabolism and clearance, possessing an elimination half-life of roughly 4 to 5 hours. In contrast, the (R)-enantiomer—armodafinil—exhibits a prolonged elimination half-life approximating 12 to 15 hours. Consequently, the administration of armodafinil yields sustained plasma concentrations that persist into the late afternoon and evening, resolving the midday therapeutic trough frequently documented with racemic formulations.
5. Historical Development
The lineage of armodafinil traces back to pioneering neuropharmacological research conducted in France during the 1970s. Scientists at Laboratoire L. Lafon, led by experimental medicine professor Michel Jouvet and chemist Louis Lafon, synthesized a novel series of benzhydryl sulfinyl compounds designed to produce non-amphetamine psychostimulation. This initiative culminated in the identification of adrafinil, a prodrug that metabolized in vivo into modafinil. Modafinil demonstrated exceptional efficacy in sustaining vigilance without the peripheral autonomic agitation typical of classical stimulants, earning clinical approval in France during the early 1990s and subsequently securing United States Food and Drug Administration (FDA) approval in 1998 under the brand name Provigil.
As the molecular mechanisms and clinical kinetics of modafinil were systematically characterized, researchers recognized the disparate biological fates of its constituent stereoisomers. Clinical pharmacokinetic assays demonstrated that following racemic administration, the inactive or rapidly cleared (S)-isomer contributed minimally to therapeutic maintenance during the latter half of the waking day, while burdening hepatic clearance pathways. Recognizing the potential for enhanced pharmacokinetic predictability, Cephalon, Inc. pursued the chiral isolation and development of the isolated (R)-enantiomer.
Throughout the early 2000s, multicenter, double-blind, randomized clinical trials assessed the safety, tolerability, and wakefulness-promoting efficacy of armodafinil across diverse patient populations suffering from excessive daytime sleepiness. These extensive clinical programs demonstrated that armodafinil provided superior wakefulness profiles later in the diurnal cycle relative to comparable doses of racemic modafinil. The United States FDA granted formal approval to armodafinil (under the brand name Nuvigil) in June 2007 for the treatment of excessive sleepiness associated with narcolepsy, obstructive sleep apnea (OSA), and shift work sleep disorder (SWSD), formally establishing the enantiopure compound as a cornerstone of sleep medicine.
6. Theoretical Foundations
The therapeutic operation of armodafinil is contextualized within the neurobiological model of the “sleep-wake flip-flop switch,” a theoretical paradigm formulated by Clifford B. Saper and colleagues. This model posits that sleep and wakefulness are governed by mutually inhibitory neuronal networks that operate analogously to an electronic bistable switch. The wake-promoting network comprises ascending monoaminergic pathways (locus coeruleus noradrenaline, dorsal raphe serotonin, and tuberomammillary histamine) alongside basal forebrain cholinergic neurons and lateral hypothalamic orexin/hypocretin projections. Conversely, the sleep-promoting center is consolidated within the ventrolateral preoptic nucleus (VLPO), which discharges inhibitory GABA and galanin to quiet arousal centers.
Armodafinil conceptually stabilizes this bistable circuit in the “on” state through dual actions: it augments upstream monoaminergic tone while directly dampening the somnogenic drive of the VLPO. By indirectly disinhibiting orexinergic neurotransmission, armodafinil reinforces the structural stability of the flip-flop mechanism. This prevents sudden, unintended transitions into non-rapid eye movement (NREM) or rapid eye movement (REM) sleep, which represent the hallmark neurobiological failure observed in individuals with central disorders of hypersomnolence.
From an information-processing and cognitive neurobiology perspective, armodafinil is understood through the lens of the Yerkes-Dodson Law and the neurochemical modulation of prefrontal cortical networks. The prefrontal cortex (PFC) requires optimal concentrations of dopamine and norepinephrine to sustain executive functioning, working memory, and vigilance; either sub-optimal or excessive catecholamine levels degrade signal-to-noise ratios, precipitating cognitive blunting or behavioral disorganization. Armodafinil elevates extracellular dopamine within physiological windows, enhancing cognitive focus and sustained attention without tipping cortical networks into the hyper-aroused states associated with amphetamine-induced neurotoxicity or cognitive inflexibility.
7. Key Components, Types & Dimensions
The pharmacological, structural, and physiological dimensions of armodafinil encompass multiple distinct operational domains:
- Stereochemical Architecture: Armodafinil is an enantiopure organic compound featuring a stereocenter localized at the chiral sulfur atom of the sulfinyl bridge. Its designation as the (–)-(R)-enantiomer denotes its specific levorotatory optical rotation and spatial configuration, distinguishing it physically and pharmacologically from the dextrorotatory (+)-(S)-enantiomer.
- Pharmacokinetic Profile: The compound demonstrates high oral bioavailability with peak plasma concentrations (Tmax) achieved roughly two hours post-administration under fasting conditions. Its terminal elimination half-life spans 12 to 15 hours, exhibiting linear, dose-proportional pharmacokinetics across standard therapeutic ranges (50 mg to 250 mg daily).
- Hepatic Metabolism: Biotransformation occurs predominantly through non-CYP hydrolytic pathways—yielding modafinil acid and modafinil sulfone as inactive metabolites—with partial participation of Cytochrome P450 (CYP) enzymes, specifically CYP3A4/5.
- Enzyme Induction and Inhibition: Armodafinil exhibits complex metabolic interactions, acting as a moderate inducer of hepatic CYP3A4 enzymes and a reversible inhibitor of CYP2C19. This dual metabolic footprint creates clinically significant drug interaction potential, notably attenuating the efficacy of steroidal oral contraceptives while elevating systemic concentrations of drugs cleared via CYP2C19 (such as diazepam, omeprazole, and phenytoin).
- Neurochemical Dimensions: Its therapeutic mechanisms involve selective, atypical dopamine transporter inhibition, downstream excitation of histamine and orexin pathways, potentiation of cortical glutamatergic signaling, and modest attenuation of local GABAergic inhibition.
8. Examples & Illustrative Cases
The clinical implementation of armodafinil spans several complex patient presentations where wakefulness is pathologically compromised by neurodegenerative, anatomical, or circadian disruptions:
Case Illustration 1: Residual Sleepiness in Obstructive Sleep Apnea
A 52-year-old male corporate executive presents with refractory daytime hypersomnolence despite strict, documented adherence to continuous positive airway pressure (CPAP) therapy (usage averaging >6.5 hours per night, with an apnea-hypopnea index reduced below 3 events per hour). Despite anatomical correction of his upper airway obstruction, the patient struggles to sustain concentration during afternoon meetings, scoring 16 on the Epworth Sleepiness Scale (ESS). Following comprehensive clinical evaluation excluding secondary sleep disorders, adjunctive therapy with armodafinil at 150 mg once daily every morning is initiated. Within two weeks, the patient reports sustained alertness throughout his entire workday without nocturnal insomnia, and his follow-up ESS score declines to 7, reflecting normalized vigilance.
Case Illustration 2: Shift Work Sleep Disorder in Healthcare Workers
A 34-year-old emergency department nurse transitioning to permanent nocturnal shifts (19:00 to 07:00) experiences severe lapses in attention, microsleeps during early morning shift hours, and hazardous drowsiness while driving home at sunrise. Cognitive behavioral strategies for circadian adjustment provide only partial relief. Initiating armodafinil at 150 mg administered approximately one hour prior to the commencement of each nocturnal work shift produces a substantial attenuation of subjective and objective fatigue during critical working windows. The intervention eliminates workplace microsleeps, preserves acute decision-making capacity, and enhances commuter safety while preserving scheduled daytime sleep periods.
9. Measurement & Assessment
Evaluating the therapeutic efficacy, neurocognitive impact, and physiological safety of armodafinil requires a combination of subjective psychometric instruments, objective neurophysiological sleep assessments, and rigorous clinical monitoring protocols.
In standard clinical practice, subjective daytime somnolence is systematically measured using validated psychometric questionnaires. The primary screening and monitoring metric is the Epworth Sleepiness Scale (ESS), an 8-item self-administered scale evaluating an individual’s likelihood of dozing off across common sedentary situations. Reductions of four or more points on the ESS typically indicate clinically meaningful therapeutic responses to armodafinil. Additionally, researchers employ the Clinical Global Impression of Improvement (CGI-I) scale and the Functional Outcomes of Sleep Questionnaire (FOSQ) to gauge broader socioeconomic and quality-of-life advancements.
Objective quantification of armodafinil’s wake-promoting potency relies on standardized neurophysiological assessments conducted in specialized sleep laboratories:
- Maintenance of Wakefulness Test (MWT): The gold-standard objective metric utilized in clinical trials for regulatory approval. Patients are placed in an isolated, soporific environment and instructed to resist sleep across four to five 40-minute sessions spaced throughout the day. Armodafinil reliably demonstrates a statistically significant extension in mean sleep onset latency relative to placebo.
- Multiple Sleep Latency Test (MSLT): Employed primarily in the initial diagnostic validation of narcolepsy, measuring the speed of sleep onset and sleep-onset REM periods (SOREMPs) across five daytime nap opportunities.
- Psychomotor Vigilance Task (PVT): A high-temporal-resolution behavioral assessment evaluating sustained visual attention and reaction time, frequently demonstrating that armodafinil significantly reduces attention lapses and stabilizes executive response latency under conditions of sleep deprivation.
Physiological monitoring necessitates routine baseline and interval evaluations of blood pressure and heart rate due to rare elevations in sympathetic tone. Dermatological screening is essential during initial therapy to identify any emergent cutaneous adverse reactions.
10. Applications & Practical Significance
The primary clinical applications of armodafinil are anchored in formal regulatory approvals across modern medicine. In patients with type 1 and type 2 narcolepsy, armodafinil serves as a first-line eugeroic pharmacotherapy to alleviate profound daytime sleepiness, though it does not manage the auxiliary symptom of cataplexy (which requires distinct monoaminergic or oxybate interventions). In obstructive sleep apnea, it serves as an adjunctive pharmaceutical option to mitigate residual hypersomnolence when gold-standard positive airway pressure therapy has successfully eliminated mechanical airway collapse but failed to fully restore daytime energy. In shift work sleep disorder, it acts as a targeted circadian wake-promoting agent that counteracts mismatched circadian timing during occupational wake periods.
Beyond approved labels, armodafinil is widely investigated and prescribed off-label across diverse neuropsychiatric conditions. In bipolar depression, multiple randomized, double-blind trials have explored adjunctive armodafinil to target residual depressive symptoms and cognitive slowing, demonstrating notable improvements in depressive symptom scores without triggering manic destabilization or rapid mood cycling when combined with standard mood stabilizers. Similarly, it is prescribed off-label for fatigue associated with major depressive disorder, multiple sclerosis, post-stroke recovery, and cancer-related fatigue syndromes.
In occupational, military, and aerospace contexts, armodafinil possesses profound utility for maintaining alertness during continuous, long-duration operational missions where sustained cognitive processing and situational awareness are critical to safety. Its minimal cardiovascular burden and absence of significant motor impairment make it an advantageous candidate for aviation and high-risk environments relative to historic amphetamine protocols.
11. Research & Empirical Evidence
The clinical efficacy and molecular mechanisms of armodafinil have been validated through rigorous randomized controlled trials, systematic reviews, and meta-analyses. Groundbreaking clinical investigations led by researchers such as Thomas Roth, Charles Czeisler, and Philip Hirshkowitz established the empirical framework for the compound’s clinical adoption.
In pivotal Phase III clinical trials evaluating armodafinil in patients with obstructive sleep apnea who exhibited residual sleepiness despite CPAP adherence (Roth et al., 2006; Hirshkowitz et al., 2007), armodafinil (150 mg and 250 mg daily) generated statistically significant improvements over placebo in mean sleep latency on the Maintenance of Wakefulness Test. Notably, these therapeutic benefits were robustly preserved during the final testing sessions in the late afternoon, illustrating sustained late-day efficacy. Patient-reported overall wakefulness, assessed via the Epworth Sleepiness Scale, showed concordant, statistically significant enhancements, which were accompanied by measurable improvements in patient-reported global functioning and productivity metrics.
In studies evaluating shift work sleep disorder (Czeisler et al., 2005), individuals randomized to armodafinil 150 mg administered one hour before night shifts displayed significant reductions in nocturnal sleepiness on both the MWT and the Clinical Global Impression scale. Furthermore, neurocognitive testing via the Psychomotor Vigilance Task demonstrated significant reductions in lapse frequency and reaction time degradation during the biological circadian nadir (04:00 to 07:00). Long-term open-label extension studies spanning up to twelve months have corroborated that armodafinil maintains its wakefulness-promoting efficacy without evidence of pharmacological tolerance, tachyphylaxis, or severe withdrawal syndromes upon planned discontinuation.
12. Cultural & Cross-Cultural Considerations
The cultural perception, regulatory classification, and sociopolitical status of armodafinil vary considerably across geographic borders. In the United States, the Drug Enforcement Administration (DEA) categorizes armodafinil as a Schedule IV controlled substance under the Controlled Substances Act, recognizing its low potential for abuse and dependence relative to Schedule II classical stimulants like amphetamines. In contrast, jurisdictions such as the United Kingdom, Canada, Australia, and many member states of the European Union regulate armodafinil as a prescription-only medicine (POM) without placing it on strict controlled-substance registries, reflecting differing legal standards regarding psychological dependence risks.
Cross-cultural differences also emerge within competitive academic and high-stakes corporate environments. In various societies, armodafinil is increasingly discussed as a “smart drug” or cognitive enhancer. This phenomenon has catalyzed an informal global market in nootropic substances, raising cross-cultural bioethical dilemmas regarding cognitive fairness, academic integrity, and pharmaceutical coercion. While Western bioethicists vigorously debate whether voluntary pharmacological cognitive enhancement represents individual autonomy or an inequitable advantage, other cultures emphasize occupational compliance, where wakefulness agents may be subtly incentivized to meet extreme corporate productivity expectations in highly competitive professional ecosystems.
13. Criticisms, Debates & Limitations
Despite its proven therapeutic profile, armodafinil remains the focus of several clinical debates, safety warnings, and methodological criticisms. One primary pharmacological debate centers on whether the isolated (R)-enantiomer offers genuine superiority over racemic modafinil. Critical pharmacologists argue that many clinical trials contrasting armodafinil with historical modafinil data leveraged dose comparisons that were not milligram-for-milligram bioequivalent. They argue that higher, divided doses of racemic modafinil might approximate the late-day plasma levels of armodafinil, implying that the clinical advantages may represent incremental pharmacokinetic refinements rather than groundbreaking pharmacodynamic breakthroughs.
From a safety standpoint, armodafinil carries formal warnings regarding serious cutaneous adverse reactions. Although exceptionally rare, life-threatening dermatological emergencies—including Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and drug reaction with eosinophilia and systemic symptoms (DRESS)—have been documented during post-marketing surveillance of modafinil and armodafinil. These reactions necessitate immediate, permanent discontinuation at the earliest sign of a skin rash. Additionally, psychiatric complications—including anxiety, agitation, insomnia, de novo depression, and rare instances of psychotic or manic exacerbation—have been reported, particularly in individuals with pre-existing affective or psychotic vulnerabilities.
A notable clinical limitation involves armodafinil’s moderate induction of CYP3A4 enzymes. This pharmacokinetic alteration accelerates the systemic metabolism of ethinyl estradiol and progestin, drastically reducing the reliability of hormonal contraceptives. This risk demands comprehensive clinical counseling and the mandatory implementation of non-hormonal barrier methods in patients of childbearing potential, highlighting a notable challenge in family planning management.
14. Related Terms & Distinctions
Navigating the clinical pharmacology of wakefulness requires differentiating armodafinil from closely aligned pharmaceutical entities:
- Racemic Modafinil: The 1:1 mixture of both (R)- and (S)-enantiomers. While modafinil shares armodafinil’s core indications, its shorter elimination half-life results in lower afternoon plasma drug levels compared to armodafinil when dosed once in the morning.
- Adrafinil: A synthetic prodrug metabolized in vivo into modafinil. Adrafinil carries a substantially higher risk of hepatotoxicity due to extensive hepatic processing, requires much higher doses, and has largely been withdrawn from formal clinical medicine.
- Dextroamphetamine / Amphetamine Salts: Direct central nervous system stimulants acting via competitive monoamine reverse transport and vesicular release. Amphetamines demonstrate far higher sympathomimetic toxicity, pronounced cardiovascular strain, substantial rebound hypersomnia, and a much greater risk of dependence and addiction (Schedule II in the United States).
- Methylphenidate: A classic dopamine and norepinephrine reuptake inhibitor that, while sharing DAT binding properties, binds through different kinetic profiles, exhibiting higher abuse liability and pronounced peripheral autonomic activity compared to armodafinil.
- Solriamfetol: A dual dopamine and norepinephrine reuptake inhibitor approved for excessive daytime sleepiness in narcolepsy and OSA. Solriamfetol does not affect CYP3A4 enzymes, sparing hormonal contraceptives from metabolic degradation, but possesses distinct noradrenergic cardiovascular properties.
- Pitolisant: An inverse agonist/antagonist at the histamine H3 autoreceptor. Unlike armodafinil, pitolisant promotes wakefulness by directly liberating endogenous neuronal histamine and acetylcholine without binding to the dopamine active transporter.
15. Summary / Key Takeaways
Armodafinil represents an advanced eugeroic agent engineered via chiral isolation of the long-acting (R)-enantiomer of modafinil. By selectively engaging the dopamine transporter with slow-dissociation kinetics and systematically mobilizing hypothalamic orexin, histamine, and monoamine networks, armodafinil stabilizes vigilance and executive function. Its pharmacokinetic signature yields prolonged plasma concentrations, ensuring sustained wakefulness across afternoon and evening hours without inducing the physiological volatility, peripheral cardiovascular strain, or addiction potential characteristic of conventional sympathomimetic psychostimulants.
Approved for the treatment of excessive daytime sleepiness across narcolepsy, obstructive sleep apnea, and shift work sleep disorder, armodafinil is characterized by a favorable safety profile when appropriately monitored. Key clinical considerations include its potential to reduce the efficacy of hormonal contraceptives through CYP3A4 induction, rare possibilities of severe dermatological reactions, and mild dopaminergic side effects such as headache, nausea, and insomnia. In aggregate, armodafinil exemplifies how rational stereochemical engineering can refine therapeutic pharmacokinetics to optimize waking function in human sleep medicine.
References
- Czeisler, C. A., Walsh, J. K., Roth, T., Dinges, D. F., Drake, C. L., Rajagopalan, K., Chen, D., & Black, J. E. (2005). Modafinil for excessive sleepiness associated with shift-work sleep disorder. The New England Journal of Medicine, 353(5), 476–486. https://doi.org/10.1056/NEJMoa041292
- Darwish, M., Kirby, M., Robertson, P., & Hellriegel, E. T. (2009). Armodafinil and modafinil have substantially different pharmacokinetic profiles despite having the same terminal half-lives: Analysis of data from three randomized, single-dose, pharmacokinetic studies. Clinical Drug Investigation, 29(9), 613–623. https://doi.org/10.2165/11315280-000000000-00000
- Hirshkowitz, M., Black, J. E., Wesnes, K., Niebler, G., & Arora, S. (2007). Adjunct armodafinil improves wakefulness and memory in obstructive sleep apnea/hypopnea syndrome. Respiratory Medicine, 101(3), 616–627. https://doi.org/10.1016/j.rmed.2006.06.012
- Roth, T., White, D., Schmidt-Nowara, W., Wesnes, K. A., Niebler, G., & Arora, S. (2006). Effects of armodafinil in the treatment of residual excessive sleepiness associated with obstructive sleep apnea/hypopnea syndrome: A 12-week, multicenter, double-blind, randomized, placebo-controlled study in CPAP-adherent patients. Clinical Therapeutics, 28(5), 689–706. https://doi.org/10.1016/j.clinthera.2006.05.013
- Saper, C. B., Chou, T. C., & Scammell, T. E. (2001). The sleep switch: Hypothalamic control of sleep and wakefulness. Trends in Neurosciences, 24(12), 726–731. https://doi.org/10.1016/S0166-2236(00)02002-6
- United States Food and Drug Administration. (2007). Nuvigil (armodafinil) tablets: Prescribing information. U.S. Department of Health and Human Services. https://www.accessdata.fda.gov/
- Volkow, N. D., Fowler, J. S., Logan, J., Alexoff, D., Zhu, W., Telang, F., Wang, G. J., Jayne, M., Hooker, J. M., Wong, C., Hubbard, B., Carter, P., Warner, D., King, P., Shea, C., Xu, Y., Muench, L., & Apelskog-Torres, K. (2009). Effects of modafinil on dopamine and dopamine transporters in the male human brain: Clinical implications. JAMA, 301(11), 1148–1154. https://doi.org/10.1001/jama.2009.351